PharmaTutor (May- 2014)
ISSN: 2347 - 7881
Received On: 15/12/2013; Accepted On: 10/03/2014; Published On: 01/05/2014
Author: S. Ramya Silpa
Department of Pharmacology,
Balaji College of Pharmacy, Anantapur, AP, India.
shilpasankarapu@gmail.com
ABSTRACT:
Prostaglandins are potent bioactive lipid messengers synthesized from arachidonic acid mediated by enzyme COX. Prostaglandins (PGs) play a key role in the initiation of the inflammatory response. Their biosynthesis is significantly increased in inflamed tissue, and they contribute to the development of the cardinal signs of acute inflammation. Although the proinflammatory properties of individual PGs during the acute inflammatory response are well established, their role in the resolution of inflammation is more controversial.
How to cite this article: SR Silpa; Prostaglandins and its Types; PharmaTutor; 2014; 2(5); 31-37
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Olivier Morteau. Prostaglandins and Inflammation: the Cyclooxygenase Controversy. Archivum Immunologiae et Therapiae Experimentalis. 2000; 48: 473–480
2.Daniel l. Simmons, Regina M. Botting, and Timothy Hla. cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. Pharmacol Rev 2004; 56:387–437
3.Pawel Kalinski. Regulation of Immune Responses by Prostaglandin E 2. The Journal of Immunology 2012; 188: 21–28.
4.Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56: 387–437.
5.Kurt J. Sales and Henry N. Jabbour. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction. 2003 November ; 126(5): 559–567.
6.Hecker M, Foegh ML, Ramwell PW. The eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes and related compounds. In Basic and Clinical Pharmacology. Katzung, B.G. Eds; Appleton & Lange, Norwalk, CT 1995; pp 290-304.
7.Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem. 2000; 69:145–182.
8.Joan Clària. Cyclooxygenase-2 Biology. Current Pharmaceutical Design 2003; 9:2177-2190
9.T. D. Warner and J. A. Mitchell, “Cyclooxygenase-3 (COX- 3): filling in the gaps toward a COX continuum?” Proceedings of the National Academy of Sciences of the United States of America 2002; 99(21):13371–13373.
10.R. G. Kurumbail, J. R. Kiefer, and L. J. Marnett. “Cyclooxygenase enzymes: catalysis and inhibition,” Current Opinion in Structural Biology. 2001; 11(6): 752–760
11.K. Gupta, B. S. Selinsky, C. J. Kaub, A. K. Katz, and P. J. Loll, “The 2.0 a resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase,” Journal ofMolecular Biology. 2004; 335(2): 503–518
12.R. M. Garavito and A. M. Mulichak. “The structure of mammalian cyclooxygenases,” Annual Review of Biophysics and Biomolecular Structure. 2003;32:183–206
13.Tanabe T and Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostagl Other Lipid Mediat 2002;68-69:95–114.
14.W. Ma and J. C. Eisenach. “Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain,” European Journal of Neuroscience. 2002; 15(6): 1037–1047
15. W. Ma and R. Quirion. “Does COX2-dependent PGE2 play a role in neuropathic pain?” Neuroscience Letters 2002; 437(3): 165–169.
16.Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm. 2002; 65:149–165.
17.Sales, K.J. et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, PGE receptors and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002; 62: 424–432
18.Kirschenbaum, A. et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 671–676.
19.Chulada, P.C. et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000; 60: 4705–4708
20.Kitamura, T. et al. Inhibitory effects of mofezolac, a cyclooxygenase- 1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002; 23: 1463–1466
21.Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179–191.
22.Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99:13926–13931.
23.Schwab JM, Schluesener HJ, Meyermann R and Serhan CN .COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot Essent Fatty Acids 2003a; 69:339–343.
24.Park, J. Y., M. H. Pillinger, S. B. Abramson. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol 2006; 119: 229–240.
25.Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9:744–749.
26.Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally requiredfor human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 2006; 176:966–973.
27.Backlund, M. G., J. R. Mann, V. R. Holla, F. G. Buchanan, H. H. Tai, E. S. Musiek, G. L. Milne, S. Katkuri, and R. N. DuBois. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem 2005; 280: 3217–3223.
28.Hirsch, F. R., and S. M. Lippman. Advances in the biology of lung cancer chemoprevention. J. Clin. Oncol 2005; 23: 3186–3197.
29.Tseng-Rogenski, S., J. Gee, K. W. Ignatoski, L. P. Kunju, A. Bucheit, H. J. Kintner, D. Morris, C. Tallman, J. Evron, C. G. Wood, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am. J. Pathol 2010; 176: 1462–1468.
30.Eruslanov, E., S. Kaliberov, I. Daurkin, L. Kaliberova, D. Buchsbaum, J. Vieweg, and S. Kusmartsev. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J. Immunol 2009; 182: 7548–7557.
31.Yan, M., S. J. Myung, S. P. Fink, E. Lawrence, J. Lutterbaugh, P. Yang, X. Zhou, D. Liu, R. M. Rerko, J. Willis, et al. 2009. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl. Acad. Sci. USA 106: 9409–9413.
32.Fujino, H., S. Salvi, and J. W. Regan. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol 2005; 68: 251–259.
33.Sugimoto Y, Narumiya S. Prostaglandin E receptors. J. Biol. Chem 2007;282:11613–11617.
34.Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 2007;320:22–28.
35.Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518–523.
36.North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007;447:1007–1011.
37.Kojima F, Kato S, Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 2005;19:255–261.
38.Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. J Immunol 2007;178:8138–8147.
39.Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871–1875.
40. en.wikipedia.org/wiki/Prostaglandin
41. Tripathi KD., 2008. Essentials of Medical Pharmacology, sixth ed. New Delhi. pp -179
42. Tripathi KD., 2008. Essentials of Medical Pharmacology, sixth ed. New Delhi. pp 178.
43.T. J. Montine, K. R. Sidell, B. C. Crews et al. “Elevated CSF prostaglandin E2 levels in patients with probable AD.” Neurology 1999; 53(7): 1495–1498
44. Tripathi KD., 2008. Essentials of Medical Pharmacology, sixth ed. New Delhi. pp 177.
45. en.wikipedia.org/wiki/Prostaglandin_I2
46.Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in Vascular Diseases. Circ J 2010; 74:836–843.
47.Emanuela Ricciotti and Garret A. FitzGeraldProstaglandins and Inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000
48.Noda M, Kariura Y, Pannasch U, Nishikawa K, Wang L, Seike T, Ifuku M, Kosai Y, Wang B, Nolte C, Aoki S, Kettenmann H, Wada K. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem 2007; 101:397–410.
49.Doi Y, Minami T, Nishizawa M, Mabuchi T, Mori H, Ito S. Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. NeuroReport 2002; 13:93–96.
50.Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O’Yang C, Smith S, Srinivasan D, Ford AP, Jett MF. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 2006; 147:335–345.
51. Tsuyoshi Oguma, Koichiro Asano and Akitoshi Ishizaka Role of Prostaglandin D2 and Its Receptors in the Pathophysiology of AsthmaAllergology International. 2008;57:307-312
52. Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm. 2000;58:89-120.
53. Hilary Sandig, James E. Pease, and Ian Sabroe. Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function J. Leukoc. Biol. 81: 372–382; 2007.
54. Ye Chun Ruan,1,2 Wenliang Zhou,1 and Hsiao Chang Chan2Regulation of Smooth MuscleContraction by the Epithelium: Role of Prostaglandins, physiology 2011,26;156-70
.png)
